Get the Stockscreener App
0.1072
34.35%
-0.0561
After Hours:
.10
-0.0072
-6.72%
Aditxt Inc stock is traded at $0.1072, with a volume of 16.44M.
It is down -34.35% in the last 24 hours and down -83.30% over the past month.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$0.1633
Open:
$0.15
24h Volume:
16.44M
Relative Volume:
5.42
Market Cap:
$743.10K
Revenue:
$749.50K
Net Income/Loss:
$-29.60M
P/E Ratio:
-0.000285
EPS:
-376.0263
Net Cash Flow:
$-22.09M
1W Performance:
-60.15%
1M Performance:
-83.30%
6M Performance:
-96.85%
1Y Performance:
-99.14%
1-Day Range:
$0.102
$0.156
1-Week Range:
$0.102
$0.264
52-Week Range:
$0.102
$14.10
Aditxt Inc Stock (ADTX) Company Profile
Name
Aditxt Inc
Sector
Industry
Phone
909-488-0844
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Aditxt Inc Stock (ADTX) Latest News
Aditx Therapeutics stock hits 52-week low at $0.15 - Investing.com
Aditxt Inc (ADTX) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
How should investors view Aditxt Inc (ADTX)? - US Post News
Closing Figures: Aditxt Inc (ADTX)’s Negative Finish at 0.16, Down -25.60 - The Dwinnex
why Aditxt Inc [ADTX] is a Good Choice for Investors After New Price Target of $61.00 - The DBT News
Aditxt (NASDAQ:ADTX) Shares Scheduled to Reverse Split on Wednesday, October 2nd - Defense World
Aditxt announces 1-for-40 reverse stock split - Investing.com
Aditxt announces 1-for-40 reverse stock split - TipRanks
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024 | ADTX Stock News - StockTitan
Evofem Biosciences Inc. (OTCQB: EVFM) Stock On Watchlist After Announcing A Key Update - DRP Journal
Aditxt aims for Q4 merger with Evofem Biosciences - Investing.com
ADTX’s Stochastic Averages Dip: Analyzing Aditxt Inc’s Stock Performance - The InvestChronicle
Evofem Biosciences files proxy for stockholder approval of acquisition by Aditxt - TipRanks
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt | ADTX Stock News - StockTitan
Aditxt secures new financing and expands collaboration with Evofem By Investing.com - Investing.com South Africa
Aditxt secures new financing and expands collaboration with Evofem By Investing.com - Investing.com Canada
Aditxt secures new financing and expands collaboration with Evofem - Investing.com India
Aditxt secures new financing and expands collaboration with Evofem - Investing.com
Aditxt and Evofem partner to launch endometriosis diagnostic in 2025 - Medical Device Network
Understanding ADTX’s financial ratios: A beginner’s guide - US Post News
Market Highlights: Aditxt Inc (ADTX) Ends on a Low Note at 0.38 - The Dwinnex
There is no way Aditxt Inc (ADTX) can keep these numbers up - SETE News
Aditxt (NASDAQ:ADTX) Stock Quotes, Forecast and News Summary - Benzinga
ADTX’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
ADTX stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com Australia
Aditxt's Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 - Quantisnow
ADTX stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com
ADTX stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com Canada
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest? - Yahoo Finance
Raymond James lifts Adma Biologics Inc [ADMA] price estimate. Who else is bullish? - The DBT News
Addentax Group Corp. (NASDAQ:ATXG) Short Interest Down 17.9% in August - Defense World
Keeping an Eye on Adma Biologics Inc (ADMA) After Insider Trading Activity - Knox Daily
AdaptHealth Stock Earns RS Rating Upgrade - MSN
Adma Biologics Inc (NASDAQ:ADMA) stock crossing the finish line today - US Post News
Analog Devices, Inc. (NASDAQ:ADI): A Chip Stock Powering The AI Boom - Insider Monkey
Analytical Overview: Adma Biologics Inc (ADMA)’s Ratios Tell a Financial Story - The Dwinnex
DekaBank Deutsche Girozentrale Sells 6,400 Shares of Amdocs Limited (NASDAQ:DOX) - Defense World
Analog Devices is Citi's new top semiconductor pick - Investing.com
Digital Health Acquisition (NASDAQ:DHAC) Trading Down 2.5% - Defense World
Automatic Data Processing Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Adma Biologics Inc (ADMA) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Adma Biologics Inc (ADMA) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News
DEADLINE ALERT for ABR, FIVE, DXC, and INDV: The Law - GlobeNewswire
In the Green: Aditxt Inc (ADTX) Closes at 0.45, Up/Down -10.00 from Previous Day - The Dwinnex
A Closer Look at Aditxt Inc (ADTX) Stock Gains - The InvestChronicle
Q2 2026 EPS Estimates for Analog Devices, Inc. Decreased by Analyst (NASDAQ:ADI) - MarketBeat
Adobe Shares Decline Amid AI Software Concerns - Invezz
AvidXchange Holdings Inc. (AVDX): Best New Tech Stock To Buy Now - Insider Monkey
Adtran Holdings Inc. (ADTN): Best Emerging Tech Stock to Buy Now - Insider Monkey
Automatic Data Processing Inc. stock rises Friday, still underperforms market - MarketWatch
Aditxt Inc Stock (ADTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):